Meller, Birgit

[["dc.bibliographiccitation.firstpage","223"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Oezerden, M. M."],["dc.contributor.author","Braune, I."],["dc.contributor.author","Kluge, G."],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:14:40Z"],["dc.date.available","2018-11-07T09:14:40Z"],["dc.date.issued","2012"],["dc.description.abstract","The prevalence of cervical lymphadenopathy in autoimmune thyroiditis (AIT) patients is actually unknown. The aim of the study was the detailed retrospective evaluation of 6 index-patients with lymphadenopathy in Robbins level VI and a prospective study with high resolution ultrasound of lymphadenopathy in All patients compared with controls in all compartments of the neck, accessible to sonographic evaluation. Patients, methods: The retrospective study comprises six patients with AIT, evaluated for enlarged Robbins level VI-LN. We report the findings of fine-needle aspiration Cytology, clonal analysis, histology, and serological testing. The prospective study evaluated the prevalence of lymphadenopathy in 49 consecutive patients with AIT (group 1) and 49 consecutive patients with normal thyroids or nontoxic goiter (group2). Results: In the retrospective study, cytology of paratracheal LN revealed reactive lymphoid hyperplasia in 5/6 of the cases and a centroblastic lymphoma in one patient. The presence of monoclonal lymphatic cells was excluded in 5/6 patients and proven in 1/6 patients. Actual viral-infections were ruled out. In the prospective study All-patients showed significantly more enlarged LN in Robbins level II-IV and VI compared to controls. We found no correlation between lymphadenopathy, age, thyroid volume and nodularity, or autoantibody levels. During follow-up in 34 group 1-patients, lymphadenopathy remained stable in 28 patients, and decreased in 6 patients. Conclusion: Lymphadenopathy in Robbins level II-IV and VI is common in AIT-patients and most probably related to the autoimmune process."],["dc.identifier.doi","10.3413/Nukmed-0484-12-03"],["dc.identifier.isi","000312613800004"],["dc.identifier.pmid","23042429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Patients with autoimmune thyroiditis Prevalence of benign lymphadenopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Lisney, Anna Rebecca; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Leitsmann, Conrad; 2Department of Urology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; conrad.leitsmann@med.uni-goettingen.de (C.L.); astrauss@med.uni-goettingen.de (A.S.)"],["dc.contributor.affiliation","Strauß, Arne; 2Department of Urology, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; conrad.leitsmann@med.uni-goettingen.de (C.L.); astrauss@med.uni-goettingen.de (A.S.)"],["dc.contributor.affiliation","Meller, Birgit; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Bucerius, Jan Alexander; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.affiliation","Sahlmann, Carsten-Oliver; 1Department of Nuclear Medicine, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; anna.lisney@med.uni-goettingen.de (A.R.L.); birgit.meller@med.uni-goettingen.de (B.M.); jan.bucerius@med.uni-goettingen.de (J.A.B.)"],["dc.contributor.author","Lisney, Anna Rebecca"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauß, Arne"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bucerius, Jan Alexander"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2022-08-04T08:33:18Z"],["dc.date.available","2022-08-04T08:33:18Z"],["dc.date.issued","2022-07-26"],["dc.date.updated","2022-08-03T12:10:10Z"],["dc.description.abstract","The combination of positron emission tomography (PET)-diagnostics with ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic milestone in the situation of biochemical recurrence of prostate cancer and is gaining importance in primary diagnostics, providing a highly specific and sensitive diagnostic method in various clinical situations. However, the clinical application of this method requires a comprehensive knowledge of its advantages and disadvantages, potential pitfalls and influencing factors. This review aims to provide a practical clinical review of the currently available background data on PSMA PET/CT, as well as the clinical implications. Although a large amount of data already exist, a thorough analysis is complicated by study heterogeneity, showing the need for future systematic and prospective research.\r\n \r\n \r\n Abstract\r\n The importance of PSMA PET/CT in both primary diagnostics and prostate cancer recurrence has grown steadily since its introduction more than a decade ago. Over the past years, a vast amount of data have been published on the diagnostic accuracy and the impact of PSMA PET/CT on patient management. Nevertheless, a large heterogeneity between studies has made reaching a consensus difficult; this review aims to provide a comprehensive clinical review of the available scientific literature, covering the currently known data on physiological and pathological PSMA expression, influencing factors, the differences and pitfalls of various tracers, as well as the clinical implications in initial TNM-staging and in the situation of biochemical recurrence. This review has the objective of providing a practical clinical overview of the advantages and disadvantages of the examination in various clinical situations and the body of knowledge available, as well as open questions still requiring further research."],["dc.identifier.doi","10.3390/cancers14153638"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112630"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","66"],["dc.bibliographiccitation.journal","EJNMMI Research"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:48:52Z"],["dc.date.available","2018-11-07T09:48:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro in order to get an insight of the interactions between altered premedication and PSMA expression before repetitive PSMA-directed PET/CT for therapy response and targeted therapy implementation. Methods: The human castration-resistant PCa cell line VCaP (CRPC) was treated with either 1 nmol/L testosterone (T) over 20 passages yielding the androgen-sensitive cell line (revCRPC) or with 5 mu mol/L abiraterone acetate (AA) generating the abiraterone-tolerant subtype CRPCAA. In these cell lines, T and AA were varied by either supply or withdrawal of T and AA. PSMA expression of the three cell culture models was detected by Western blot and immunohistochemical staining. For quantitative measurement of tracer uptake, 0.3 nmol/L Ga-68-labelled PSMA-HBED-CC peptide (100-300 kBq/ml) was added to different treated parallel cultures (n = 9 each). Time-dependent uptake per 10(6) cells of each culture was calculated and evaluated. PSMA mRNA expression was investigated by qPCR. Results: PSMA expression increased dependently on intensified ADT in all three basic cell lines. Ga-68-PSMA-HBED-CC uptake almost doubled during 3 h in all cell lines (p < 0.01). Compared to the basic cells, pre-incubation with abiraterone for 48 h resulted in a significant increased uptake in CRPC (p < 0.001). In revCRPC, 48-h AA pre-incubation resulted in an eightfold higher uptake after 3 h (p < 0.001). Additional withdrawal of external testosterone increased the uptake up to tenfold (p < 0.01). The increase of PSMA expression upon ADT and AA treatments was confirmed by qPCR and Western blot data. Furthermore, in CRPCAA, 48-h AA withdrawal increased the uptake up to fivefold (p < 0.01). Conclusions: The investigated three PCa cell culture subtypes represent a serial preclinical model of androgen deprivation therapy as a proxy for clinical situations with differing basal PSMA expression. The uptake of PSMA-binding tracers could be stimulated by therapeutic effective short-term variation in premedication in all stages of ADT response. These complex interactions have to be considered in the interpretation of diagnostic imaging using PSMA ligands as well as in the optimal timing of PSMA-based therapies."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [TH 389/3-1, BR4700/1-1]"],["dc.identifier.doi","10.1186/s13550-015-0145-8"],["dc.identifier.isi","000364963600001"],["dc.identifier.pmid","26576996"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12584"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35393"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","2191-219X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","242"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten"],["dc.contributor.author","Ritter, Carsten"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Braune, Isabell"],["dc.date.accessioned","2018-11-07T10:19:48Z"],["dc.date.available","2018-11-07T10:19:48Z"],["dc.date.issued","2016"],["dc.description.abstract","The diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge. The aim of this study was to evaluate the role of F-18-FDG-PET/CT in patients with unexplained elevated C-reactive protein with or without fever. Contribution of F-18-FDG-PET/CT to the final diagnosis was evaluated. In addition we determined whether a differentiation between patients with or without fever is clinically reasonable. Patients, methods: We retrospectively analysed 72 consecutive patients with unexplained elevated C-reactive protein levels (above 8mg/l) that underwent F-18-FDG-PET/ CT in our facility between 10/2009 and 11/2012. 18F-FDG-PET/CT was considered a so-called diagnostic scan when results decisively led to a final diagnosis and adequate therapy with a response of symptoms was initiated due to the PET/CT result. Results: In 60/72 patients (83%) a final diagnosis was established. Diagnoses included infections (58%), non-infectious inflammatory diseases (29%) and malignancies (8%). F-18-FDG-PET/CT was true positive in 47 cases (65%) and the diagnostic scan in 29 patients (40%). Sensitivity of 18F-FDG-PET/CT was 81% and specificity was 86%. Diagnostics, final diagnoses, F-18-FDG-PET/CT results, SUVmax, C-reactive protein levels and the diagnostic scan did not differ significantly between patients with fever and patients without fever. Conclusion: F-18-FDG-PET/CT is a useful method in the diagnostic workup of patients with inflammation of unknown origin. In our series there was no significant difference between patients with or without fever. Regarding F-18-FDG-PET/CTimaging inflammation of unknown origin and unexplained fever can be joined to one entity."],["dc.identifier.doi","10.3413/Nukmed-0798-16-02"],["dc.identifier.eissn","2567-6407"],["dc.identifier.isi","000389621900006"],["dc.identifier.issn","0029-5566"],["dc.identifier.pmid","27617327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41740"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0029-5566"],["dc.title","F-18-FDG-PET/CT in unexplained elevated inflammatory markers"],["dc.title.alternative","Joining entities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","459"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Braz J Urol"],["dc.bibliographiccitation.lastpage","467"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-06-01T10:48:28Z"],["dc.date.available","2021-06-01T10:48:28Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: 68Ga-PSMA PET/CT imaging is a promising modality for the staging of recurrent prostate cancer (PCa). Current evidence suggests limited diagnostic value of the 68Ga-PSMA PET/CT in PSA-levels ≤0.3ng/mL. Experimental data have demonstrated an increase in PSMA-expression in PCa metastases by androgen deprivation in vitro. The aim of the current study was to investigate a possible enhancing effect of PSMA with low-dose androgen deprivation in patients with BCR and low PSA-levels. Materials and Methods: Five patients with PCa and BCR, following radical prostatectomy, underwent 68Ga-PSMA PET/CT. A consecutive 68Ga-PSMA PET/CT was performed 6 to 11 days after injection of 80mg of Degarelix (Firmagon®). We recorded PSA and testosterone serum-levels and changes of PSMA-uptake in 68Ga-PSMA PET/CT images. Results: Median PSA prior 68Ga-PSMA PET/CT was 0.27ng/mL. All patients had a decrease in testosterone serum levels from median 2.95μg/l to 0.16μg/l following Degarelix injection. We observed an increase in the standardized uptake value (SUV) in PSMA-positive lymphogenous and osseous lesions in two patients following androgen deprivation. In another two patients, no PSMA positive signals were detected in either the first or the second scan. Conclusion: Our preliminary results of this feasibility assessment indicate a possible enhancing effect of PSMA-imaging induced by low-dose ADT. Despite several limitations and the small number of patients, this could be a new approach to improve staging by 68Ga-PSMA PET/CT in PCa patients with BCR after primary therapy. Further prospective studies with larger number of patients are needed to validate our findings."],["dc.identifier.doi","10.1590/s1677-5538.ibju.2018.0305"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85949"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1677-6119"],["dc.relation.issn","1677-5538"],["dc.title","Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","40"],["dc.bibliographiccitation.journal","Frontiers in Medicine"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten O."],["dc.contributor.author","Meller, Johannes"],["dc.date.accessioned","2019-07-09T11:50:07Z"],["dc.date.available","2019-07-09T11:50:07Z"],["dc.date.issued","2019"],["dc.description.abstract","Infective endocarditis displays a serious condition with high mortality rates. Establishing a reliable diagnosis can be challenging. This study evaluates granulocyte imaging with 99mTc-Besilesomab-SPECT/CT in order to determine the clinical value of the method and its possible redefinition through the addition of hybrid imaging. The study comprises 26 consecutive patients with suspected infectious endocarditis or prosthetic valve infection that underwent 99mTc-Besilesomab-SPECT/CT in our facility between December 2016 and September 2018. 99mTc-Besilesomab-SPECT/CT images were reviewed by two independent and blinded observers and results were evaluated by transesophageal echocardiography (TEE) and blood culture results as well as by pathological, bacteriological, and clinical findings. Target-to-Background-Ratios were calculated for semi-quantitative analysis. 13/26 patients were in a post-surgical stage. 99mTc-Besilesomab-SPECT/CT was positive in 6 cases. All 6 cases were true positive confirmed by pathological or clinical findings according to the modified Duke Criteria for infective endocarditis. Remaining 19/26 cases were true negative. Target-to-Background ratios were significantly higher in patients that were visually scored positive compared to negative cases. Inter-observer agreement was very good of deciding whether a scan was positive or negative. Sensitivity of 99mTc-Besilesomab-SPECT/CT was 86–100% and specificity was 100%. 99mTc-Besilesomab-SPECT/CT is a useful imagingmethod for the diagnosis of endocarditis, especially in difficult cases with prosthetic valves or cardiac devices and inconclusive findings in echocardiography. The added value of SPECT/CT was mainly finding and localizing increased uptake at a certain valve, prosthesis, or device cable."],["dc.identifier.doi","10.3389/fmed.2019.00040"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15861"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59704"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","2296-858X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","99mTc-Besilesomab-SPECT/CT in Infectious Endocarditis: Upgrade of a Forgotten Method?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","198"],["dc.bibliographiccitation.issue","05"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","203"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten"],["dc.contributor.author","Wolf, Bettina"],["dc.contributor.author","Langer, Laura"],["dc.contributor.author","Bankstahl, Jens"],["dc.contributor.author","Wester, Hans"],["dc.contributor.author","Kropf, Saskia"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Bouter, Caroline"],["dc.date.accessioned","2020-12-10T18:47:26Z"],["dc.date.available","2020-12-10T18:47:26Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3413/Nukmed-0971-18-04"],["dc.identifier.eissn","2567-6407"],["dc.identifier.issn","0029-5566"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78765"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT"],["dc.title.alternative","Der immunhistochemische Nachweis CXCR4-exprimierender Lymphozyten bei chronischer Osteomyelitis bestätigt einen spezifischen Uptake in der 68Ga-Pentixafor-PET/CT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T11:24:50Z"],["dc.date.available","2018-11-07T11:24:50Z"],["dc.date.issued","2009"],["dc.format.extent","S404"],["dc.identifier.isi","000208690802128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56493"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Labelling of the bispecific trivalent monoclonal antibody TF2 and the TF2 binding hapten IMP288 for in vitro and in vivo investigations in colorectal cancer (Immuno SPET, PET and radioimmuno therapy)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Sharkey, R. M."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T08:51:26Z"],["dc.date.available","2018-11-07T08:51:26Z"],["dc.date.issued","2011"],["dc.format.extent","S243"],["dc.identifier.isi","000208619400553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21933"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Automatized Ga-68-Labeling of the Hapten-Peptide, IMP288, for Radioimmuno-PET Trials to Evaluate Therapeutic Response"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]